Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Willing and able to provide written informed consent, or, if deemed lacking in the capacity to provide informed consent, the following requirements for consent must be met:
Has completed the Double-Blind Treatment Period of an antecedent study with ML-007C-MA (ie, ML-007C-MA-221).
May benefit from long-term therapy with open-label ML-007C-MA treatment, in the judgment of the investigator.
Has a designated study care partner who is in contact with the participant frequently enough to accurately report on the participant's symptoms and adherence to study drug.
Resides in a stable living environment (eg, home, residential assisted living, or nursing home facility) and is expected to remain in the living situation throughout the study.
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
210 participants in 1 patient group
Loading...
Central trial contact
Clinical Trials Contact Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal